European Outsourcing Revenue to Grow by 50% - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

European Outsourcing Revenue to Grow by 50%


ePT--the Electronic Newsletter of Pharmaceutical Technology

A new report from Frost & Sullivan has forecast that the utilization rates of pharmaceutical manufacturing plants will decrease by half in upcoming years, triggering an increase in outsourcing.

According to the report, European Pharmaceutical and Biotech Contract Manufacturing Markets, the European pharmaceutical contract manufacturing market could earn revenues of up to $20.75 billion in 2018, almost double that of 2011’s revenue when the market earned $10.02 billion. Over the same period, the European market for biotechnology outsourcing is forecast to grow from $1.21 billion to $2.67 billion.

The trends towards reduced facility utilization and increased outsourcing are partly being driven by the expiration of blockbuster drugs. Another Frost & Sullivan report has forecast that drugs worth $150 billion will go off patent between 2010 and 2017. Currently, large pharmaceutical companies contribute to around 10–25% of the total revenues for contract manufacturing organizations in Europe, but this could rise to 40% by 2013 and to 50% by 2018.

“As pharmaceutical and biotech companies strive to enhance their internal core competencies, outsourcing is likely to become increasingly entrenched as a strategic manufacturing option,” said Frost & Sullivan research analyst Aiswariya Chidambaram in a statement. “The impact of the economic crisis, coupled with the poor performance of the venture capital industry in Europe, has underlined the popularity of contract manufacturing as it has become synonymous with cost-cutting and the timely entry of products into the market.”

Frost & Sullivan expects the market prospects for contract manufacturers to be “buoyant” with a compound annual growth rate of 10.9% from 2011–2018. Biotechnology will also experience high growth—12.1% over the same period. However, contract manufacturers will have to be careful not to end up with over capacity. Aiswariya said, “Although the demand for manufacturing capacity is rising, a careful weighing of benefits and risks is required by CMOs while planning capacity expansions lest they be hit by over capacity, which, in turn, could lead to the acquisition of smaller CMOs by larger ones.”

See related Pharm Tech articles:

Global Market Boom for Generic Drugs (ePT)

Contract Services in 2012 (Pharm Tech)

Troublesome Signs for Bio/Pharma R&D (Pharm Tech)

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here